-
Pacira Pharmaceuticals (PCRX) PT Raised to $55 at BMO Capital, Following Earnings
-
Pacira Pharmaceuticals (PCRX) PT Lowered to $43 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $46 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Lowered to $44 at BMO Capital
-
Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Pacira Pharmaceuticals (PCRX) PT Raised to $47 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $34 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Lowered to $31 at BMO Capital
-
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
-
Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
-
Pacira Pharmaceuticals (PCRX) Exparel Sales 'Good' Versus Expectations - BMO
-
Paciraa (PCRX) October Exparel Data Suggests Q4 at Risk - BMO Capital
-
BMO Capital Upgrades Pacira Pharmaceuticals (PCRX) to Market Perform
-
BMO Capital Starts Pacira Pharmaceuticals (PCRX) at Underperform
-
Pre-Open Stock Movers 12/6: (ENZN) (GERN) (PSUN) Higher; (IOC) (ULTA) (PWRD) Lower (more...)